The U.S. Food and Drug Administration has granted approval for a new drug targeting the mutations that drive more than 90% of ...

The Pancreatic Cancer Action Network responds to FDA approval of Rasonque™ (daraxonrasib) for patients with previously ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit discusses what she learned at the inaugural AACR Drug Discovery ...

Every so often, there is a breakthrough in cancer research that changes what people believe is possible. For pancreatic cancer, that moment is now. The recent news about a new oral therapy, ...

For decades, pancreatic cancer research was defined by what seemed to be impossible. Researchers couldn’t target the mutations in the RAS family of proteins that drive more than 90% of cases. Often ...

When Jane Talbot talks about pancreatic cancer, she doesn’t just speak as a volunteer or advocate. She speaks as a wife, a mother, a grandmother and someone who will do anything to end this disease.

Editor’s note: Chicago Advocacy Chair Joanne Zborowski spoke with PanCAN’s Paula Mukherjee about her personal connection to PanCAN’s mission and advice for others who have lost a loved one to ...

Scientific discovery depends on a research system that is rigorous, transparent and guided by experts. Today, that system is at risk. The administration, through the Office of Management & Budget, has ...